Interpace Biosciences, Inc. (IDXG)
OTCMKTS: IDXG · Delayed Price · USD
1.030
-0.190 (-15.57%)
Jul 22, 2024, 9:42 AM EDT - Market open
Interpace Biosciences Employees
Interpace Biosciences had 108 employees as of December 31, 2023. The number of employees increased by 14 or 14.89% compared to the previous year.
Employees
108
Change (1Y)
14
Growth (1Y)
14.89%
Revenue / Employee
$376,481
Profits / Employee
$8,509
Market Cap
4.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
IDXG News
- 2 months ago - Interpace Biosciences Announces First Quarter 2024 Financial and Business Results - GlobeNewsWire
- 4 months ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results - GlobeNewsWire
- 1 year ago - Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement - GlobeNewsWire
- 1 year ago - Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023 - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results - GlobeNewsWire